# A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

> **NCT00670189** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 53 (actual)

## Conditions studied

- Hedgehog Pathway
- Smoothened
- Basal Cell Carcinoma (BCC)
- Basal Cell Nevoid Syndrome (BCNS)

## Interventions

- **DRUG:** BMS-833923 (XL139)

## Key facts

- **NCT ID:** NCT00670189
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-05
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2014-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670189, "A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00670189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*